The present invention refers to a process to obtain a three-dimensional (3D) biodressing comprising the steps of (a) isolating and culturing mesenchymal cells with human AB serum; (B) performing three-dimensional (3D) bioprinting using a biomaterial such as sodium alginate and cells obtained in step a; (c) putting at rest the 3D biodressing obtained after bioprinting; (d) covering the 3D biodressing with a 100 mM calcium chloride solution; (e) washing the 3D biodressing; (f) adding Dulbecco's Modified Eagle Medium (DMEM); and (g) keeping the biodressing in an incubator for up to 15 days. Additionally, the present invention refers to the 3D biodressing obtained comprising, preferably 4% sodium alginate and mesenchymal cells from the umbilical cord (MCUs), which has healing, anti-inflammatory, and analgesic properties. Furthermore, the present invention relates the 3D biodressing to treat patients with chronic wounds and severe burns.

The present invention provides compositions and methods useful in the treatment of wounds, particularly in reducing or preventing scar formation, particularly hypertrophic scar or keloid formation. The invention thus further provides methods of treatment, including methods useful in hypertrophic scar or keloid revision as well as prophylactic, scar inhibiting methods.

The present invention relates to a hemostatic absorbable composition, comprising: a flowable plurality of separate aggregates each comprising: a plurality of absorbable carrier particles coated on a surface thereof by a plurality of smaller particles comprising an absorbable supplemental hemostasis-promoting agent. In some embodiments, the absorbable carrier particles comprise gelatin or collagen, and the supplemental hemostasis-promoting agent comprises oxidized cellulose, oxidized regenerated cellulose, carboxylic oxidized cellulose, carboxylic oxidized regenerated cellulose, thrombin, or tranexamic acid.

Bifunctional modified biopolymer based polymer comprise at least one polymer chain comprising n first functional groups and m second functional groups. The first functional groups comprise groups able of being radically cross-linked following a free radical chain-growth polymerisation. The second functional groups comprise groups able to thiol-ene crosslinking. Preferred bifunctional modified biopolymer based polymers comprise bifunctional modified gelatin and bifunctional modified collagen. The invention further relates to a method to prepare such a bifunctional modified biopolymer based polymer and to a method to prepare a hydrogel starting from such bifunctional modified biopolymer based polymer. Furthermore the invention relates to hydrogels obtainable starting from such bifunctional modified biopolymer based polymers and to the use of such hydrogels.

Gels which include a first gelatin component and a second gelatin component in an aqueous medium are described, wherein the first gelatin component includes gelatin particles having chemical cross-links and dehydrothermal cross-links, and the second gelatin component includes a dissolved gelatin having chemical cross-links and at least one polysaccharide.

The invention relates to hemostatic compositions comprising ellagic acid-metal complex and uses thereof for activating the intrinsic pathway of blood coagulation. In particular, disclosed are hemostatic compositions comprised of ellagic acid complexed with nickel ions, the complex being dispersed or embedded within an absorbable polymeric matrix such as gelatin. Further disclosed are method for making the hemostatic compositions.

A novel active agent-eluting hemostatic agent and methods of use and manufacture thereof are presented. A polymer, such as gelatin, is used as the base for a hemostatic agent. The gelatin is crosslinked with a chemical crosslinker, such as a carbodiimide, in the presence of an active agent. The active agent may be an anesthetic or antimicrobial, such as an antibiotic. The novel process allows for the active agent to be both covalently bound to the gelatin as well as be trapped within cages in the gelatin that are formed from the crosslinking. This dual measure allows for controlled and sustained release of the active agent from the hemostatic agent to reduce surgical site infections.

A hemostatic sponge comprising crosslinked gelatin and/or gelatin/chitosan, a method for manufacturing it, and methods of its use.

A method of manufacturing hemostatic particles involves heating and mixing a chitosan solution and a gelatin solution to form a chitosan/gelatin solution, adding the chitosan/gelatin mixture to oil containing an emulsifier/surfactant to form a combination of chitosan/gelatin and oil, heating and mixing the combination and then cooling and stirring the combination to form gelatin-chitosan microspheres (GCM), adding an aqueous solution of glutaraldehyde to the combination and stirring to cross-link the GCM, washing the GCM with emulsifier/surfactant to remove the oil, washing the GCM with a solvent to further remove excess oil, washing the GCM with alcohol to remove excess water, and drying the GCM.

The present invention addresses the problem of providing a powder that has excellent adhesive strength to biological tissue when applied to a wound-covering material or the like. The present invention also addresses the problem of providing a wound-covering material and an adhesion prevention material. The powder contains particles containing a crosslinked gelatin derivative, wherein the gelatin derivative has a structure represented by formula (1): GltnNH-L-CHR1R2 (in the formula, Gltn represents a residue of gelatin, L represents a single bond or a divalent linking group, R.sup.1 represents a hydrocarbon group having 1-20 carbon atoms, and R.sup.2 represents a hydrogen atom or a hydrocarbon group having 1-20 carbon atoms), the particles have an average sphericity of 1.45 or less, and the standard deviation of the sphericity of the particles is 0.25 or less.